AUTHOREA
Log in Sign Up Browse Preprints
LOG IN SIGN UP
Shivani Singh
Shivani Singh
Joined Oct 2021

Public Documents 1
Niclosamide - a promising treatment for COVID-19
Shivani Singh
Anne Weiss

Shivani Singh

and 8 more

October 12, 2021
Vaccines have reduced the transmission and severity of COVID-19 but there remains a paucity of efficacious treatment for drug resistant strains and more susceptible individuals. Repurposing existing drugs is a timely, safe and scientifically robust method for treating pandemics such as COVID-19. Here, we review the pharmacology and scientific rationale for repurposing niclosamide, an anti-helminth already in human use as a treatment for COVID-19. In addition to potent antiviral activity, niclosamide has shown pleiotropic anti-inflammatory, antibacterial, bronchodilatory and anticancer effects in numerous pre-clinical and early clinical studies. The advantages and rationale for nebulised and intranasal formulations of niclosamide, which target the site of primary infection in COVID-19, are reviewed. Finally, we discuss the TACTIC-E clinical trial, an international COVID-19 therapeutic platform trial for the use of licensed and novel therapeutic agents, which is investigating niclosamide as a promising candidate against SARS-CoV-2.
Authorea
  • Home
  • About
  • Product
  • Preprints
  • Pricing
  • Blog
  • Twitter
  • Help
  • Terms of Use
  • Privacy Policy